Platelet-rich plasma for the treatment of scleroderma-associated ulcers: a single-center experience and literature review
Accepted: 4 February 2024
SUPPLEMENTARY MATERIAL: 40
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Systemic sclerosis (SS) is a complex connective tissue disease characterized by vasculopathy and progressive fibrosis, primarily considered an autoimmune disorder. SS can affect multiple organs and tissues, including the skin, respiratory, gastrointestinal, genitourinary, cardiovascular, and musculoskeletal systems. Skin involvement is common, and SS-related ulcers, especially digital ulcers, occur in roughly 50% of patients. These ulcers not only cause pain but also significantly impact patients' quality of life, and in severe cases, they can lead to infection, gangrene, and amputation. The search for novel therapies for scleroderma-related ulcers remains an ongoing research area. Platelet-rich plasma (PRP) has been investigated as a potential treatment for difficult-to-heal ulcers, including diabetic, pressure, and vascular ulcers. In this study, we share our experience in treating scleroderma ulcers with PRP. Ten patients with confirmed SS and chronic skin ulcers lasting at least six weeks, which had not responded to conventional treatments, were selected for the study. Homologous PRP gel was prepared and applied once a week for up to eight weeks. The ulcers were documented photographically before and after PRP treatment, and pain levels were assessed using a visual analog scale (VAS). We also conducted a systematic review of the literature focusing on the use of PRP in the setting of SS. The results from our casuistry showed that the ten patients, including eight females and two males with a median age of 52.5 years, had ulcer sizes ranging from 0.78 cm2 to 28.26 cm2. The ulcers were located on fingers, legs, and heels, and they were associated with various forms of SS, including limited and diffuse cutaneous involvement. Raynaud's phenomenon was prevalent, and two patients exhibited organ involvement. The average ulcer size at the end of PRP treatment decreased significantly, with a 78% reduction in ulcered area. Pain levels also markedly improved, as indicated by a reduction in VAS scores. With regards to systematic revision of literature, we retrieved 45 cases of SS treated with PRP-based therapeutic regimes. However, only a minority of them (n=16) underwent PRP treatment for the treatment of SS-related ulcers. An improvement in wound size and pain has been documented in all cases. Taken together, these data highlight the potential benefits of using homologous PRP in the treatment of scleroderma ulcers, emphasizing its positive impact on ulcer size reduction and pain relief.
Kowalska-Kępczyńska A. Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics. J Clin Med. 2022;11(9):2299. doi:10.3390/jcm11092299 DOI: https://doi.org/10.3390/jcm11092299
Giuggioli D, Manfredi A, Lumetti F, Colaci M, Ferri C. Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature. Autoimmun Rev. 2018;17(2):155-164. doi:10.1016/j.autrev.2017.11.020 DOI: https://doi.org/10.1016/j.autrev.2017.11.020
Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909 DOI: https://doi.org/10.1136/annrheumdis-2016-209909
Hesseler MJ, Shyam N. Platelet-rich plasma and its utility in medical dermatology: A systematic review. J Am Acad Dermatol. 2019;81(3):834-846. doi:10.1016/j.jaad.2019.04.037 DOI: https://doi.org/10.1016/j.jaad.2019.04.037
Matucci-Cerinic M, Krieg T, Guillevin L, et al. Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Ann Rheum Dis. 2016;75(10):1770-1776. doi:10.1136/annrheumdis-2015-208121 DOI: https://doi.org/10.1136/annrheumdis-2015-208121
Costedoat I, Masson M, Barnetche T, et al. Locoregional Treatments for Digital Ulcers in Systemic Sclerosis: A Systematic Review. Acta Derm Venereol. 2021;101(6):adv00478. doi:10.2340/00015555-3839 DOI: https://doi.org/10.2340/00015555-3839
Paganelli A, Contu L, Condorelli A, et al. Platelet-Rich Plasma (PRP) and Adipose-Derived Stem Cell (ADSC) Therapy in the Treatment of Genital Lichen Sclerosus: A Comprehensive Review. Int J Mol Sci. 2023;24(22):16107. doi:10.3390/ijms242216107 DOI: https://doi.org/10.3390/ijms242216107
Meznerics FA, Fehérvári P, Dembrovszky F, et al. Platelet-Rich Plasma in Chronic Wound Management: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Clin Med. 2022;11(24):7532. doi:10.3390/jcm11247532 DOI: https://doi.org/10.3390/jcm11247532
Motolese A, Vignati F, Antelmi A, Saturni V. Effectiveness of platelet-rich plasma in healing necrobiosis lipoidica diabeticorum ulcers. Clin Exp Dermatol. 2015;40(1):39-41. doi:10.1111/ced.12474 DOI: https://doi.org/10.1111/ced.12474
Abellan Lopez M, Philandrianos C, Daumas A, et al. Assessing the effect of PRP addition to facial micro-lipofilling for patients suffering from Scleroderma: A prospective routine care analysis. Ann Chir Plast Esthet. 2023;68(2):152-161. doi:10.1016/j.anplas.2022.07.016 DOI: https://doi.org/10.1016/j.anplas.2022.07.016
Pirrello R, Verro B, Grasso G, et al. Hyaluronic acid and platelet-rich plasma, a new therapeutic alternative for scleroderma patients: a prospective open-label study. Arthritis Res Ther. 2019;21(1):286. doi:10.1186/s13075-019-2062-0 DOI: https://doi.org/10.1186/s13075-019-2062-0
Virzì F, Bianca P, Giammona A, et al. Combined platelet-rich plasma and lipofilling treatment provides great improvement in facial skin-induced lesion regeneration for scleroderma patients. Stem Cell Res Ther. 2017;8(1):236. doi:10.1186/s13287-017-0690-3 DOI: https://doi.org/10.1186/s13287-017-0690-3
Kanemaru H, Kajihara I, Yamanaka K, et al. Platelet-rich plasma therapy is effective for the treatment of refractory skin ulcers in patients with systemic sclerosis. Mod Rheumatol. 2015;25(4):660-661. doi:10.3109/14397595.2014.924204 DOI: https://doi.org/10.3109/14397595.2014.924204
Giuggioli D, Colaci M, Manfredi A, Mariano M, Ferri C. Platelet gel in the treatment of severe scleroderma skin ulcers. Rheumatol Int. 2012;32(9):2929-2932. doi:10.1007/s00296-011-2038-0 DOI: https://doi.org/10.1007/s00296-011-2038-0
Shetty S, Shenoi SD. Autologous platelet-rich fibrin in treatment of scleroderma ulcer. Int Wound J. 2016;13(5):1065-1066. doi:10.1111/iwj.12480 DOI: https://doi.org/10.1111/iwj.12480
Palumbo VD, Rizzuto S, Damiano G, et al. Use of platelet concentrate gel in second-intention wound healing: a case report. J Med Case Rep. 2021;15(1):85. doi:10.1186/s13256-020-02649-6 DOI: https://doi.org/10.1186/s13256-020-02649-6
Wang HC, Li Z, Li Z, Wang X, Long X. Platelet-Rich Plasma Combined Fat Transplantation for the Treatment of Bleomycin-Induced Murine Scleroderma. Ann Plast Surg. 2023;90(6):626-630. doi:10.1097/SAP.0000000000003579 DOI: https://doi.org/10.1097/SAP.0000000000003579
Daumas A, Magalon J, Delaunay F, et al. Fat Grafting for Treatment of Facial Scleroderma. Clin Plast Surg. 2020;47(1):155-163. doi:10.1016/j.cps.2019.08.016 DOI: https://doi.org/10.1016/j.cps.2019.08.016
Serratrice N, Bruzzese L, Magalon J, et al. New fat-derived products for treating skin-induced lesions of scleroderma in nude mice. Stem Cell Res Ther. 2014;5(6):138. doi:10.1186/scrt528 DOI: https://doi.org/10.1186/scrt528
Macko RF, Gelber AC, Young BA, et al. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol. 2002;29(12):2565-2570.
Copyright (c) 2024 the Author(s)
![Creative Commons License](http://i.creativecommons.org/l/by-nc/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.